SCIEX Presents Novel QTOF Mass Spectrometry System for Simpler and Faster Biotherapeutics Characterisation

SCIEX focuses on reproducible data and education for biologics labs with the X500B QTOF at World ADC Summit

(PresseBox) ( Darmstadt, )
SCIEX, a global leader in life science analytical technologies, featured the X500B Quadrupole Time-of-Flight (QTOF) System at the 7th World ADC Summit, which was recently held in Berlin, Germany. The new technology provides simple, high quality and robust biotherapeutics characterisation that makes quantitative analysis accessible to pharmaceutical laboratories of all sizes. SCIEX experts also provided educational sessions for delegates at the summit to help further scientists’ understanding of how LC-MS technologies can improve the quality of ADC characterisation by delivering reliable, trusted results.

In the midst of increasing regulatory requirements for biotherapeutics development and manufacturing, scientists are continually looking for ways to improve the quality, reliability and reproducibility of characterisation data. The X500B QTOF System was specifically developed to deliver ease-of-use for high resolution standardised workflows for biotherapeutic developers, who are required to fully characterise biologic products in large numbers during the development process. The compact and user-friendly system includes powerful BioPharmaViewTM 2.0 processing software that simplifies complex data processing, resulting in faster generation of meaningful information. The software can also be used to interpret SWATH® 2.0 data independent acquisition on the X500B QTOF System. SWATH Acquisition allows comprehensive peptide mapping data to be acquired for every peptide in the sample from a single injection, including important low-abundance peptides and post-translational modifications that may be missed with other approaches.

Other innovative SCIEX solutions for biologics were featured at the World ADC Summit, including the PA 800 Plus Pharmaceutical Analysis System that provides automated quantitative analysis of biotherapeutics for development and quality control processes. The capillary electrophoresis system is proven within the industry to provide robust QA/QC for many capillary electrophoresis applications including characterisation of product purity, charge heterogeneity and glycan analysis. Glycan analysis has recently been enhanced with the launch of the Fast Glycan Labeling and Analysis Kit, which can run glycans up to five times faster than traditional HILIC approaches.

During the event, SCIEX presented a seminar entitled ‘The simpler and faster LC-MS solution for routine biopharmaceutical characterisation’ that focused on ADC development. The seminar – which was filled to capacity – gave new insights into improving ADC characterisation. Topics included ways to improve data quality while also simplifying data collection, and recent technology developments that have made mass spectrometry more accessible to routine biotherapeutics analysis.

SCIEX also held a workshop during the event, which included a presentation from Professor Yannis Francois on CESI-MS characterisation of ADCs. In this presentation Prof. Francois highlighted the use of the CESI 8000 Plus System for high-order structural interrogation of antibody-drug conjugates by a combination of intact, middle-up and bottom-up techniques using CESI-MS.

Learn more about the X500B from SCIEX at and
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an